Bhalchandra Kawdikar: FDA Approves Rusfertide for Polycythemia Vera
Bhalchandra Kawdikar, Vice President International Marketing at Edge Pharma (merchant Exporter), shared a post on LinkedIn:
”FDA Approves MIMRYLO Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera Aug 28, 2026.
Why it matters: New hope in reducing the risk of life-threatening conditions due to chronic blood cancer.
PV is a chronic blood cancer. In PV RBC’s are overproduced, increasing the blood viscosity.
This can result in life threatening thrombotic events such as stroke, deep vein thrombosis and pulmonary embolism.
Takeda’s Mimrylo (Rusfertide) is a first-in-class SC Inj. It mimics the action of hepcidin, (a natural hormone that regulates iron homeostasis and erythrocytosis).
By targeting the underlying mechanism of iron dysregulation MIMRYLO aims reduces excess RBC production and helps maintain hematocrit control.”
Stay updated with Hemostasis Today.
-
Sep 3, 2026, 15:18Massimo Martino: Redefining Allogeneic Transplantation in Myelofibrosis
-
Sep 3, 2026, 15:10Tvisha Subhasish: Extravascular Factor IX Beyond the Circulation
-
Sep 3, 2026, 11:21Thrombotic Microangiopathies: From Clinical Syndrome to Molecularly Targeted Therapy
-
Sep 3, 2026, 10:56Elias Othman: Can an Enzyme Involved in Cell Signaling Become a Target for Antithrombotic Drug Discovery?
-
Sep 3, 2026, 10:42Jared Griffard: Hemorrhagic Shock and Component Blood Transfusion
-
Sep 3, 2026, 10:31Alan Nurden: Comparing Antiplatelet and Antithrombin Therapies in Coronary Microcirculation
-
Sep 3, 2026, 08:53Jamie’s Journey Through a Decade with Immune Thrombocytopenia – ITP Support Association
-
Sep 3, 2026, 08:00Beth Meneley: When Transfusion Is Not an Option – HBOT for Exceptional Blood Loss Anemia
-
Sep 3, 2026, 06:27Seyed Mehrab Safdari: Unmasking Factor VII Padua to Prevent Unnecessary Therapy and Thrombotic Risk